This publication is a sponsored research report and constitutes a paid promotional communication. It has been prepared by Poschevale and disseminated on behalf of Guerilla Capital, which has provided compensation for the creation and distribution of this report. This report is not independent research and should not be considered objective or unbiased analysis. COMPENSATION AND CONFLICTS OF INTEREST Guerilla Capital has provided fixed cash compensation of up to CAD $15,000 to Poschevale for the preparation and distribution of this report. This compensation is not contingent on the performance, trading price, or trading volume of any securities discussed. The issuer has not paid Poschevale directly. Guerilla Capital has been compensated by the issuer(s) discussed and may own, buy, or sell securities before, during, or after publication, including transacting during periods of increased market activity following dissemination of this report, creating a significant conflict of interest. The sponsor may have reviewed the report for factual accuracy or provided input prior to publication; all opinions expressed are those of the authors. These relationships create a significant conflict of interest, and the report should be interpreted as sponsored, promotional content rather than independent research. Poschevale and its contributors do not hold, to the best of their knowledge, a direct proprietary position in the securities mentioned unless otherwise disclosed. NO INVESTMENT ADVICE, REGISTRATION STATUS, AND RISK This report is for informational purposes only and does not constitute investment, legal, tax, or financial advice, nor a recommendation to buy or sell any security. Poschevale is not registered with the Canadian Investment Regulatory Organization or any securities regulatory authority and is not a registered investment dealer or advisor. No fiduciary or advisory relationship is created, and this report does not consider the investment objectives or financial circumstances of any individual. Investing in securities, particularly small-cap, speculative, or early-stage companies, involves a high degree of risk, including the potential loss of capital. Such securities may be volatile and illiquid. Past performance is not indicative of future results. Readers should conduct independent due diligence and consult a qualified financial advisor before making investment decisions. MARKET IMPACT AND DISTRIBUTION This report forms part of a paid promotional campaign and may be distributed through email, websites, newsletters, social media platforms, and third-party channels. Such distribution may increase awareness, trading activity, and the market price of the securities discussed, potentially benefiting interested parties. Poschevale assumes no responsibility for third-party redistribution or use. CERTIFICATION OF VIEWS Poschevale Securities Research certifies that the views expressed in this report reflect the personal views of the authors regarding the subject company and its securities and have not been influenced by compensation arrangements, except as disclosed herein. FORWARD-LOOKING STATEMENTS AND SOURCES This report may contain forward-looking statements, including projections and expectations regarding future performance. These statements involve risks and uncertainties that could cause actual results to differ materially. Poschevale undertakes no obligation to update such statements. Information in this report may be derived from third-party sources believed to be reliable but has not been independently verified. No representation or warranty is made as to its accuracy, completeness, or timeliness. All opinions are subject to change without notice. Date published: April 7, 2026. LIMITATION OF LIABILITY AND REGULATORY NOTICE Neither Poschevale nor Guerilla Capital, nor their affiliates, directors, employees, or agents, accepts liability for any direct or consequential loss arising from the use of this report or reliance on its contents. This communication has not been reviewed or approved by the British Columbia Securities Commission, the Ontario Securities Commission, or any other securities regulatory authority. This report is intended for distribution within Canada only and not for distribution in the United States or where unlawful. RATING SYSTEM Any rating terminology reflects the opinions of the authors only and does not constitute a recommendation: BUY: Expected total return +15% over 12 months HOLD: Expected total return between -15% and +15% SELL: Expected total return -15% over 12 months poschevale.com Disclaimers & Disclosures ©Poschevale Securities Research 01 / 30 SPONSORED RESEARCH – NOT INDEPENDENT RESEARCH CSE: AIML Granted US patent for ECG signal-processing Healthcare, life sciences, and enterprise focus Notes: Recurring SaaS revenue model AI-driven analytics and clinical decision support Cardiac Biomarkers Market to Surpass $100 Billion by 2034 AI/ML Innovations Inc. Highlight - AI/ML Innovations AI/ML Innovations Inc. is a Canada-based artificial intelligence company focused on commercializing applied AI and machine learning solutions, with a particular emphasis on digital healthcare and diagnostic technologies . The company’s strategy centers on acquiring, incubating, and scaling AI-driven platforms that deliver measurable operational efficiencies, improved decision-making, and data-driven clinical insights for institutional and commercial clients . Its portfolio includes proprietary neural-network-based ECG signal-processing (MaxYield™), AI-powered diagnostic reporting (CardioYield™), and advanced visualization tools (Insight360™) designed to transform raw biometric data into actionable clinical outputs and improve workflow efficiency for clinicians and researchers . These technologies position AIML to address real-world healthcare challenges, moving beyond speculative use cases to tangible deployments and partner integrations. AI/ML Innovations operates primarily through a recurring-revenue, software-as-a-service model and is led by a management team with deep expertise in AI deployment, biomedical engineering, and healthcare commercialization. During 2024–2025, AI/ML Innovations continued to streamline its corporate structure and sharpen its focus on scalable, revenue-generating AI assets while maintaining its listing on the Canadian Securities Exchange. The company advanced commercialization efforts across its operating subsidiaries, emphasized intellectual property protection through provisional patent filings for core ECG signal-processing architectures , and initiated clinical pilots with major institutions such as The Hospital for Sick Children (SickKids) in Canada , alongside international regulatory and deployment progress in Jamaica . Recent corporate activity has included board and leadership updates, selective restructuring of non-core assets, and targeted partnerships to increase market penetration and long-term shareholder value. Beyond its diagnostic platform, AI/ML Innovations is building the infrastructure layer beneath the global ECG AI ecosystem, a positioning with no direct competitors. Through NeuralCloud Solutions, the company is developing ECG annotation services, AI training infrastructure, and a pre- trained model API designed to power the diagnostic tools of other cardiac AI companies, not compete with them. This structural positioning, infrastructure rather than product is the defining characteristic that separates AIML from every other cardiac AI company in the market. Investment Highlights Rating: Buy PT: C$ 0.25 Enterprise and institutional customers Deployed tech in veterinary & equine cardiac monitoring AI cardiac-care pilot with SickKids Hospital, Canada Outstanding Shares: ~254 M Market Cap +/- $7.5M CAD CEO: Paul Duffy AI healthcare deployments in Jamaica April 2026 52WEEK: 0.03-0.12 poschevale.com ©Poschevale Securities Research *Important disclosures can be found at the beginning of this report 02 / 30 OTCPK: AIMLF Risk: Very High AI/ML Innovations presents a differentiated investment opportunity anchored in the rapidly expanding global market for AI- enabled healthcare and clinical decision-support solutions, with a clear focus on commercialization rather than research-stage experimentation. Through its portfolio of operating companies, led by its MaxYield™, CardioYield™, and Insight360™ platforms, the company is addressing high-value clinical pain points in cardiac diagnostics, data interpretation, and workflow efficiency. AI/ML benefits from growing institutional demand for AI-driven healthcare tools, early validation through pilots with leading hospitals and international deployments, and a scalable SaaS-based revenue model designed for recurring, high-margin growth. Beyond its diagnostic platform, AI/ML Innovations is building the infrastructure layer beneath the global ECG AI ecosystem, a positioning with no direct competitors. Through NeuralCloud Solutions, the company is developing ECG annotation services, AI training infrastructure, and a pre-trained model API designed to power the diagnostic tools of other cardiac AI companies, not compete with them. This structural positioning, infrastructure rather than product is the defining characteristic that separates AIML from every other cardiac AI company in the market. Insight360™ in-market and generating revenue Q1 2026 Multi-species ECG validation: human, equine, and canine 55-person team across clinical, technical & commercial functions MaxYield™ is a patent-pending AI-driven ECG signal-processing engine that transforms raw cardiac data into higher-fidelity, clinically actionable signals. Using neural-network-based modeling, it extracts clinically relevant cardiac features while reducing artifacts, noise, and variability in ECG interpretation, improving both signal clarity and diagnostic confidence. MaxYield™ serves as the foundational engine powering all of AIML's platforms and integrates with existing ECG hardware and software. MaxYield™'s validation across human, equine, and canine cardiac monitoring through the Equimetrics partnership is not simply a market expansion story, it is a technical proof of model robustness. A neural network that generalises across species with fundamentally different cardiac morphologies demonstrates architectural generalisation that single-species competitors cannot claim. CardioYield™ is an AI-enabled cardiac diagnostic and reporting platform designed to streamline cardiac assessments and improve patient outcomes. Leveraging predictive analytics and machine-learning models, it uses AI to identify clinically significant events while reducing manual interpretation time and variability — supporting clinical decision-making, patient monitoring, and advancing through pilots and international regulatory pathways. Product Stack MaxYield™ is the core patented engine, everything else is built on top of it: CardioYield™: clinical Holter report automation, advancing through FDA pathways Insight360™: wellness and performance monitoring, in-market and generating revenue Q1 2026, no regulatory clearance required TrueWave.Kit SDK: OEM licensing directly to device manufacturers Annotation Services: active infrastructure business, generating revenue today Model API: pre-trained ECG neural networks via API (Q1 2027 beta), targeting the same position OpenAI's API holds in the LLM ecosystem What sets MaxYield™ apart is it works with any device (1-lead to 12-lead), any species (human, equine, canine), and any configuration . No competitor comes close. iRhythm is locked to its own hardware. Philips Cardiologs is built for Philips devices. PMcardio targets smartphone cameras only. MaxYield™ processes raw signals from any source , that is the infrastructure play. CSE: AIML Technologies poschevale.com ©Poschevale Securities Research *Important disclosures can be found at the beginning of this report 03 / 30 Neural Cloud is AIML's core AI healthcare platform for advanced cardiac data processing and clinical workflow optimization. It applies proprietary machine-learning models to raw ECG signals to enhance clarity, reduce noise, and extract clinically relevant insights — enabling faster and more accurate clinical interpretation. Designed for hospitals, clinics, and research institutions, the platform integrates scalably with existing healthcare systems. Insight360™ is an advanced visualization and analytics platform powered by MaxYield™ that converts complex cardiac datasets into intuitive, clinician-friendly outputs. By combining MaxYield™ signal processing with AI-driven analytics, it improves workflow efficiency and reporting speed while supporting clinical and research decision-making for healthcare professionals across both settings. Every Insight360™ deployment simultaneously builds AIML's proprietary ECG training corpus, compounding the value of NeuralCloud's annotation services and Model API infrastructure with each new customer. Rating: Buy C$ 0.25 AI/ML Innovations is building a vertically integrated AI infrastructure stack for cardiac data processing, interpretation, and workflow automation. Its core technologies operate as interconnected layers — not parallel products — with MaxYield™ as the foundational engine powering every platform above it. Critically, MaxYield™ is not an incremental ECG algorithm. It is a waveform-aware segmentation engine performing beat-by-beat P-wave, QRS, and T-wave annotation with full morphology scoring. Every major incumbent — Apple, Samsung, Whoop, Oura — runs rhythm classification only. MaxYield™ identifies why the heart produces a signal, not just what the rhythm is. April 2026 AI/ML Innovations Inc. Outstanding Shares: ~254 M Market Cap +/- $7.5M CAD CEO: Paul Duffy 52WEEK: 0.03-0.12 OTCPK: AIMLF PT: Risk: Very High CSE: AIML The Uncontested Infrastructure Layer poschevale.com ©Poschevale Securities Research *Important disclosures can be found at the beginning of this report 04 / 30 Rating: Buy C$ 0.25 Five well-capitalised companies compete at the ECG AI diagnostic output layer — iRhythm, Philips Cardiologs, PMcardio, Cardiomatics, and AccurKardia. Zero companies compete in the infrastructure layer beneath them. NeuralCloud is building that layer. Infrastructure companies power their ecosystem rather than compete within it. AWS earns more from providing cloud infrastructure to Netflix than Netflix earns from streaming. NeuralCloud’s target is the equivalent structural position in ECG AI: the annotation, training, and model layer every cardiac AI company depends upon but no one has built as a standalone business. April 2026 AI/ML Innovations Inc. Outstanding Shares: ~254 M Market Cap +/- $7.5M CAD CEO: Paul Duffy 52WEEK: 0.03-0.12 OTCPK: AIMLF Revenue Stream Description Target Customers Status ECG Annotation Services Regulatory-grade labelling by 16 certified ECG technicians Device manufacturers, pharma cardiac safety, academic centres Active now AI Training Infrastructure GPU compute, FDA-aligned validation pipelines, continuous learning ECG AI developers, hospital IT 2026 Model API (MaaS) Pre-trained ECG neural networks via API — the OpenAI equivalent for ECG 60+ Holter manufacturers, wearable makers, hospital IT Q1 2027 beta Results-as-a-Service: The Economic Model Based on management guidance, CardioYield™ is positioned as a potential 5–10x throughput multiplier for cardiac lab technicians . Under this framework, a technician processing approximately 3–5 Holter studies per day without AI may be able to process 25–30+ studies per day with CardioYield™, depending on workflow and implementation. The implied ROI is intended to be visible at the department level, potentially reducing the need for lengthy enterprise procurement cycles. Pricing and offering structure are based on management-provided estimates and should be considered illustrative rather than standardized Offering Price Channel Clinic SaaS subscription C$399–C$1,499/month Direct-pay clinics, private cardiology Per-screen fee C$7/screen Volume-based clinical labs Per-study ambulatory C$35/study Holter and ambulatory ECG labs Heart Check bundle C$79/patient Direct Primary Care (DPC) 48-hour Rhythm Check C$199/patient DPC patient bundle 7-day Insight Pack C$349/patient DPC patient bundle Unit Economics Example At the base SaaS tier (C$399/month), a single clinic seat unlocks capacity for 25–30 Holter studies per day versus 3–5 without AI. At C$35 per study, the incremental revenue potential from an additional 20 studies per day exceeds the monthly subscription cost within the first two working days. The business case does not require lengthy enterprise procurement: a one-week pilot makes the ROI self-evident to the lab administrator making the buying decision. DPC Go-to-Market 200+ clinic targets identified. Pipeline is MEDDICC-qualified. Sales motion is a 90-day pilot-to-platform conversion. DPC clinics make purchasing decisions at the owner-physician level, outside traditional hospital procurement cycles. Insight360™ enters this channel with no regulatory clearance required, generating revenue while simultaneously building AIML’s proprietary ECG training corpus with every deployment. PT: Risk: Very High *Figures are based on management estimates and have not been independently verified Paul Duffy, Executive Chairman & CEO Paul Duffy brings over 30 years of dynamic leadership and a proven track record in the commercialization of digital technologies. Before joining AI/ML Innovations Inc, Paul was President and Chairman of NexTech3D.AI (CSE: NTAR) and Co-founder and CEO of ARHT Media Inc. (TSXV: ART), where he demonstrated exceptional leadership in inventing, patenting, and commercializing numerous technologies using AI, AR and Holograms. Mr. Duffy's leadership will drive the company’s mission to harness the revolutionary potential of AI and ML in the burgeoning digital health and wellbeing sector and other high growth domains. Erik Suokas, COO Erik Suokas joined as COO in January 2026 following an executive search in Q4 2025. He drove approximately 275% revenue growth at Sun Nuclear through a restructured go-to-market strategy, and held senior commercial roles at Abbott Medical, St. Jude Medical, Medtronic, and Boehringer Ingelheim. He led 12+ acquisitions at Canadian Orthodontic Partners in a PE-backed environment and holds a JD/MBA from Osgoode Hall and Schulich (graduated with distinction). His cardiology commercial network overlaps directly with Dr. Paul Dorian’s. Erik’s appointment signals AIML’s transition from development-stage to commercial execution and directly addresses the execution-stage credibility gap reflected in the current valuation discount. His experience navigating FDA-regulated commercial environments directly addresses the regulatory-commercial intersection AIML operates in, a rare combination of legal, business, and clinical credentials in a single executive Dr. Alan Rabinowitz, Chief Medical Officer Dr. Alan Rabinowitz is a cardiologist and Clinical Associate Professor at St Paul's Hospital University of British Columbia, with training from the University of Cape Town and the University of Toronto, and interventional cardiology training at St. Paul’s Hospital, Vancouver. He previously served as Director of the Cardiac Intensive Care Unit at St. Paul’s and has been actively involved in various positions of healthcare leadership in quaternary health institutions, as well as actively involved in service delivery and innovation in underserved rural and remote communities. Dr. Rabinowitz also sits on the Medical Advisory Board. Dr. Rabinowitz’s work spans data-driven healthcare, AI in cardiology, and computational biology. He serves on the Canadian Cardiovascular Society AI Advisory Committee, was an advisor to the Royal College of Physicians and Surgeons of Canada, and contributes to health data trust initiatives. He is also engaged in global entrepreneurial efforts to leverage exponential technologies for innovation in healthcare, precision medicine, and collaborative public-private health initiatives. Esmat Naikyar, Chief Product Officer Esmat Naikyar brings a wealth of knowledge and enthusiasm to his role as Interim Chief Product Officer. His background showcases a strong foundation in leading start-ups that pioneer a future where AI and big data converge to transform healthcare through the design and implementation of systems that employ AI for automated decision making. Esmat is at the forefront of guiding AIML's subsidiary, Neural Cloud Solutions, in the development of advanced Neural Networks, contributing to the ongoing evolution of Artificial Intelligence and Machine Learning applications in healthcare. Terrence Lee, Chief Financial Officer Terence Lee is a Chartered Professional Accountant (“CPA”) with 11 years of progressive finance experience and in-depth knowledge reporting under International Financial Reporting Standards. Terence has worked in various financial reporting and financial planning roles, for both private and public companies, within various sectors including: Life Sciences, Health Care, Technology, and Mining. Terence holds a Bachelor of Business Administration (finance) from Simon Fraser University and a Diploma of Accounting from UBC. He obtained his CPA designation while articling with BDO Canada LLP where he specialized in financial audits of public companies. Terence is con-currently a partner at Imperium Consulting LLP, a Vancouver-based accounting and advisory firm. CSE: AIML Management poschevale.com ©Poschevale Securities Research *Important disclosures can be found at the beginning of this report 05 / 30 Rating: Buy C$ 0.25 April 2026 AI/ML Innovations Inc. Outstanding Shares: ~254 M Market Cap +/- $7.5M CAD CEO: Paul Duffy 52WEEK: 0.03-0.12 OTCPK: AIMLF PT: DC, JD, MBA Risk: Very High CSE: AIML Medical Advisory Board poschevale.com ©Poschevale Securities Research *Important disclosures can be found at the beginning of this report 06 / 30 Rating: Buy Dr. Paul Dorian MD, MSc, FRCPC, FACC — Professor of Medicine, University of Toronto; Staff Cardiologist, Division of Cardiology, St. Michael’s Hospital Dr. Paul Dorian is an internationally respected clinician–scientist with more than 35 years of experience in arrhythmia management, sudden‑cardiac‑death prevention, and cardiovascular pharmacology. A prolific investigator, he has authored 400+ peer‑reviewed publications and led landmark trials on atrial‑fibrillation therapy and cardiac arrest outcomes. Dr. Dorian has chaired guideline committees for the Canadian Cardiovascular Society (CCS) and served as Associate Editor of Circulation. At St. Michael’s Hospital he directs the Cardiac Electrophysiology Fellowship, mentoring the next generation of EP specialists. Dr. Brett Heilbron MBChB, FRCPC, FACC — Medical Director, Electrodiagnostics Program; Clinical Associate Professor, Division of Cardiology, University of British Columbia; St. Paul’s Hospital Heart Centre, Vancouver, BC Dr. Brett Heilbron completed his undergraduate degree at the University of Cape Town (South Africa), and then practiced as a rural family physician in Newfoundland and Manitoba for 4 years. He completed Internal Medicine and Cardiology training at the University of British Columbia in 1995. He has Level 3 Certification in Cardiac Computed Tomography and is a Diplomate of the Certification Board in Cardiac Computed Tomography and a Fellow of the Society of Cardiovascular Computed Tomography. He has been based at St. Paul’s Hospital since 1997, where he has a clinical practice and works in the Cardiac Catheterization Laboratory. He is Medical Director of the Electrodiagnostics program at St. Paul’s Hospital and Mount St. Joseph’s Hospital, and a Clinical Associate Professor at the University of British Columbia. He is the Cardiology Consultant for Lifelabs British Columbia. Marc W. Deyell MD, MSc FHRS FCCS — Clinical Professor, University of British Columbia; Director, Heart Rhythm Services, St. Paul’s Hospital Dr. Marc Deyell is a leading electrophysiologist and clinical researcher whose work spans ventricular‑tachycardia ablation, inherited arrhythmic syndromes, and signal‑processing innovations. As Director of EP at UBC, he supervises a multi‑disciplinary team conducting first‑in‑human trials of AI‑driven ECG analytics—research that underpins MaxYield’s validation datasets. Dr. Kim Connelly MBBS, PhD, FRACP, FRCPC — Professor of Medicine and Physiology, University of Toronto; Cardiologist and Scientist, St. Michael’s Hospital Dr. Kim Connelly is a clinician‑scientist recognized for translational research in diabetic cardiomyopathy, advanced cardiac imaging, and regenerative therapies. He directs the Cardio‑Metabolic Research Program at St. Michael’s, where his lab integrates machine‑learning biomarkers with MRI and echo phenotyping. Dr. Connelly has secured >$15 million in competitive funding and has been a key investigator on cell‑based therapy trials for heart failure. His expertise in imaging‑defined endpoints complements MaxYield’s roadmap toward AI‑image data fusion. C$0.25 April 2026 AI/ML Innovations Inc. Outstanding Shares: ~254 M Market Cap +/- $7.5M CAD CEO: Paul Duffy 52WEEK: 0.03-0.12 OTCPK: AIMLF PT: Risk: Very High CSE: AIML Summary of AIML Intellectual Property Position poschevale.com ©Poschevale Securities Research *Important disclosures can be found at the beginning of this report 07 / 30 AI/ML Innovations Inc., through its wholly owned subsidiary NeuralCloud Solutions Inc., has disclosed a layered IP strategy focused on protecting the core signal-processing, machine-learning, and reporting architecture underpinning its cardiac analytics platforms. Supported by top-tier IP counsel (Wolf Greenfield & Sacks) , the company’s portfolio is structured to cover not just a single algorithm, but the full workflow, from raw ECG ingestion to clinically actionable output, strengthening defensibility in healthcare AI. The portfolio currently consists of: Granted U.S. patent (notice of allowance) protecting the foundational ECG signal-processing architecture, alongside A suite of provisional U.S. filings designed to expand protection across neural-network design, cloud-native workflows, and adaptive clinical reporting This combination provides both near-term enforceability (via the allowed patent) and future expansion optionality (via provisionals that can be converted into full utility filings), while reflecting a high degree of technical specificity at the implementation level. Announced June 10, 2025 November 11, 2025 IP Type Provisional Patent Suite Utility Patent (Notice of Allowance) Jurisdiction United States (USPTO) United States (USPTO) Identifier Not publicly disclosed U.S. Patent No. 12,465,266 Covered Technology • Neural-network architectures for ECG denoising and signal enhancement • Cloud-native ECG preprocessing and optimization pipelines • Adaptive, rules-based + ML-based ECG reporting engines • Workflow logic for transforming raw physiological signals into structured clinical outputs • Automated identification of ECG wave properties • Beat-level morphology classification • Machine-learning-driven denoising of noisy ECG data • Mapping signal patterns to clinically meaningful rhythm conditions Strategic Importance Establishes early priority over core AI workflows; enables broad claim coverage before commercialization scale Protects the core engine that differentiates AIML’s technology; strengthens licensing and regulatory credibility Coverage MaxYield™, CardioYield™ MaxYield™, CardioYield™ Status Filed (provisional) Allowed (pending issuance) Rating: Buy C$0.25 April 2026 AI/ML Innovations Inc. Outstanding Shares: ~254 M Market Cap +/- $7.5M CAD CEO: Paul Duffy 52WEEK: 0.03-0.12 OTCPK: AIMLF AI/ML Innovations’ intellectual property is designed to protect the entire workflow of transforming raw ECG data into clinical insights, rather than a single algorithm or narrow diagnostic output. The company’s filings cover: machine-learning enhancement of raw ECG signals; granular interpretation of cardiac beats and waveforms; generation of structured clinical reports; deployment within a scalable cloud-based system . Collectively forming a stack-wide infrastructure layer. AIML’s intellectual property appears to extend beyond core signal processing into intermediate transformation layers, including feature extraction, beat-level segmentation, and waveform classification. These steps convert raw ECG data into structured representations that underpin downstream clinical interpretation. In many healthcare AI systems, this intermediate layer is both technically complex and less commoditized than end-point predictions, suggesting that protection at this stage may provide meaningful defensibility within the overall processing pipeline. In addition, the Company’s filings suggest protection over workflow orchestration and deployment architecture, including the sequencing of data ingestion, processing, model inference, and structured report generation within a unified system. This system-level approach, particularly when combined with cloud-based deployment, may be more difficult to replicate than isolated algorithmic claims, and aligns with a broader platform-oriented IP strategy that could support scalability, integration across devices, and potential licensing opportunities over time. PT: Risk: Very High CSE: AIML Competitive Moat and Defensibility Analysis poschevale.com ©Poschevale Securities Research *Important disclosures can be found at the beginning of this report 08 / 30 Rating: Buy C$0.25 April 2026 AI/ML Innovations Inc. Outstanding Shares: ~254 M Market Cap +/- $7.5M CAD CEO: Paul Duffy 52WEEK: 0.03-0.12 OTCPK: AIMLF PT: Risk: Very High AIML’s competitive positioning is best understood as a multi-layered defensibility framework, combining formal intellectual property with data, regulatory infrastructure, and clinical integration. The Company’s end-to-end approach—spanning signal processing, machine learning, and clinical reporting—reflects a platform-level architecture rather than a point-solution model, aligning with how leading healthcare AI companies build durable, long-term competitive advantages. From an intellectual property standpoint, AIML has established a structured and increasingly sophisticated filing strategy. The allowed U.S. patent provides near-term enforceability and supports licensing and partnership discussions, while a broader suite of provisional filings appears to expand protection across neural network architectures, workflow orchestration, and clinical reporting systems. These filings are understood to be significantly more detailed than the initial patent, suggesting both increasing depth and specificity in coverage. The Company’s IP strategy has been developed in collaboration with Wolf Greenfield & Sacks, a leading life sciences IP firm, which may further enhance credibility with institutional investors and potential acquirers. Limited prior art identified during prosecution may indicate relatively broad foundational claim coverage—an important consideration in an AI patent landscape where narrowly defined claims are common. Beyond formal patents, AIML’s defensibility is supported by a combination of data assets, operational infrastructure, and clinical validation. This includes a proprietary multi-source ECG dataset, structured annotation workflows supported by certified ECG technicians, early-stage device and distribution integrations, a growing portfolio of pre-trained models, and accumulating clinical evidence from institutions such as SickKids, Toronto Heart Centre, and Heartdent Jamaica. Tempus AI's model-as-a-service architecture in oncology is structurally identical to NeuralCloud's planned 2027 Model API, validating the infrastructure thesis while underscoring that the first-mover window in ECG AI infrastructure is finite and time-sensitive.While replication is theoretically possible, building a comparable ecosystem, particularly within regulated healthcare environments, would likely require significant time, coordination, and access to high-quality data. Moat Layer Description Estimated Replication Difficulty Regulatory Infrastructure Compliance + workflows 3–5 years ECG Dataset & Annotation Multi-source labeled data 5–10 years Integrations Devices & distribution Medium–High AI Models Pre-trained models Medium Clinical Validation Studies + pilots High Taken together, AIML’s moat appears to be cumulative and reinforcing, emerging from the interaction of intellectual property, data scale, regulatory positioning, and clinical integration. While still developing, this layered structure has the potential to become increasingly difficult to replicate as the Company advances toward broader commercialization. Regulatory Pathways and Barriers to Entry AIML has initiated formal regulatory pathways, including the submission of an FDA 510(k) premarket notification for its MaxYield™ platform in April 2025, and previously filed a Device Master File with the U.S. Food and Drug Administration. While regulatory approval has not yet been granted and remains subject to review, progress through these processes may represent an additional layer of defensibility, as achieving clearance in regulated healthcare environments typically requires significant validation, time, and clinical alignment. If successful, this pathway could create meaningful barriers to entry for competitors seeking to deploy similar solutions. CSE: AIML Pilots & Studies poschevale.com ©Poschevale Securities Research *Important disclosures can be found at the beginning of this report 09 / 30 Rating: Buy C$0.25 April 2026 AI/ML Innovations Inc. Outstanding Shares: ~254 M Market Cap +/- $7.5M CAD CEO: Paul Duffy 52WEEK: 0.03-0.12 OTCPK: AIMLF Since 2023, AIML’s disclosed pilots have clustered around (1) ECG signal processing/reporting workflow adoption in real clinical settings (Holter and pediatric inpatient research), and (2) adjacent validation deployments where biometrics enable new care or payment models (rehab/remote monitoring and micropayments). The 2025 pilots, in particular, are structured to generate measurable workflow outcomes (time, throughput, quality), which is typically what converts pilots into commercialization discussions. Date Association Details Nov 24, 2025 Sick Kids Apply AI-enhanced ECG processing and predictive models to pediatric cardiac data to support early detection of clinical deterioration Oct 21, 2025 Multi-location Canadian cardiology clinic Modernize Holter ECG reporting for a clinic network handling over 1,000 patient assessments per month by improving speed and accuracy. Oct 7, 2025 Toronto Heart Centre Benchmark AI-powered Holter ECG reports against existing systems to measure time savings, throughput, and diagnostic quality. Sep 30, 2025 BC Brain Wellness Program Study links between cardiac signals and neurological health using AI during supervised exercise programs. Oct 15, 2025 Heartdent Center, Jamaica Deploy AI cardiac monitoring as a low-cost clinical solution in an international cardiology practice. Nov 26, 2025 Cornerstone Physiotherapy Use AI-enhanced 1-lead ECG data to evaluate cardiac performance, recovery, and fatigue in elite athletes. Jan 17, 2024 Cornerstone Physiotherapy Deliver Canada’s first remote Long COVID rehabilitation program using wearables and AI analytics. Feb 6, 2024 TODAQ Micropayment Pilot Enable patient access to health measurements (e.g., blood pressure) through a micropayment- based digital platform integrated with AI biometrics. Jun 14, 2023 University of Alberta Monitor respiratory and vital-sign data in patients using wearable sensors and AI over extended periods. Oct 4, 2023 University Hospital of Nice, France Support a large autonomy-prevention study involving 30,000 patients using AI and wearable health data, backed by a €50,000 grant. PT: Risk: Very High *Pilot agreements, term sheets, and distribution agreements referenced in this report do not constitute binding revenue contracts and may not result in recurring commercial revenue. CSE: AIML Macro Outlook: AI-Enabled Healthcare & Diagnostics poschevale.com ©Poschevale Securities Research *Important disclosures can be found at the beginning of this report 10 / 30 The market for AI-enabled healthcare analytics, diagnostics, and clinical decision-support solutions, the core space AI/ML Innovations operates in, is experiencing strong projected growth, driven by rising healthcare data volumes, clinician shortages, demand for workflow efficiency, and accelerating adoption of AI in regulated medical environments. Market Size & Growth Forecasts The global AI in healthcare market is estimated at approximately USD 20–25 billion in 2024 and is projected to exceed USD 180–200 billion by 2030, implying a ~35–40% CAGR, as AI tools move from pilot stages into routine clinical use. The AI medical diagnostics market, including cardiac diagnostics and imaging analytics, is forecast to grow at ~30–35% CAGR, driven by demand for faster, more accurate diagnostic interpretation and reduced clinician workload. The digital health and clinical decision-support systems market is expected to surpass USD 100 billion by 2030, with AI-powered decision tools becoming foundational across hospitals, clinics, and research institutions. Remote monitoring and AI-enabled cardiac care solutions relevant to AIML’s platforms are projected to grow at ~20–25% CAGR, supported by aging populations, chronic disease prevalence, and decentralized care models. Drivers of Growth Rising clinical data complexity: Healthcare systems face exploding volumes of ECG, imaging, and biometric data, creating demand for AI tools that can extract actionable insights efficiently. Clinician capacity constraints: Workforce shortages are accelerating adoption of AI solutions that improve diagnostic speed, consistency, and workflow efficiency. Regulatory and institutional validation Increasing regulatory clarity and real-world pilots with major hospitals are enabling broader adoption of AI diagnostics in clinical environments. Shift to data-driven care: Healthcare systems are prioritizing predictive analytics and decision support to improve outcomes, reduce variability, and control costs. Perspective for AI/ML Innovations AI/ML Innovations is directly aligned with these macro trends through its focus on AI-driven cardiac signal processing, diagnostic reporting, and clinical workflow optimization. Its portfolio—anchored by Neural Cloud, MaxYield™, CardioYield™, and Insight360™—targets high-value clinical pain points where AI adoption is transitioning from experimentation to operational deployment. As healthcare systems increasingly integrate AI into diagnostics and decision support, platforms that combine proprietary algorithms, clinical validation, and scalable SaaS delivery are positioned to capture long-term value. AIML’s emphasis on regulated deployments, institutional partnerships, and recurring software revenue positions the company to participate meaningfully in the rapid expansion of AI- enabled healthcare markets while supporting measurable clinical and operational ROI. Segment Market Size (USD/Billion) CAGR Source AI in Healthcare ~22B (2024) → ~188B (2030) ~37% Grand View Research AI Medical Diagnostics ~6.5B (2024) → ~40B (2030) ~33% Fortune Business Insights Clinical Decision Support Systems (CDSS) ~7.6B (2023) → ~27B (2030) ~20% MarketsandMarkets Digital Health (AI- Enabled) ~110B (2024) → ~330B (2030) ~20% McKinsey / Statista Remote Cardiac Monitoring & AI Cardiology ~9B (2024) → ~28B (2030) ~22% Global Market Insights Rating: Buy C$0.25 April 2026 AI/ML Innovations Inc. Outstanding Shares: ~254 M Market Cap +/- $7.5M CAD CEO: Paul Duffy 52WEEK: 0.03-0.12 OTCPK: AIMLF AI/ML Innovations operates at the intersection of AI healthcare, diagnostics,